Israpafant is primarily studied for its potential therapeutic applications in the field of medicine. It is known for its role as a platelet-activating factor (PAF) receptor antagonist, which makes it a candidate for treating conditions related to inflammation and immune response. Research has explored its use in managing asthma, as it may help reduce bronchial hyperresponsiveness and inflammation in the airways. Additionally, Israpafant has been investigated for its potential benefits in treating septic shock, as it can inhibit the effects of PAF, a key mediator in the inflammatory cascade associated with this condition. Its anti-inflammatory properties also suggest possible applications in other inflammatory disorders, though further studies are needed to confirm its efficacy and safety in clinical settings.